2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2232 Clinical characteristics and secondary cytogenetic abnormalities at diagnosis and their impact on outcomes in patients with t(11;14) primary plasma cell leukemia compared with t(11;14) multiple myeloma

Daniel Packard, MD, MSc, Shaji Kumar, MD2, Saurabh Zanwar, MBBS, MD3, Prashant Kapoor, MD4, Tamer Hellou5, Angela Dispenzieri, MD6, Francis Buadi, MD7, David Dingli, MD, PhD8, Dragan Jevremovic, MD PhD9, Suzanne Hayman, MD10, Nelson Leung, MD11, Joselle M Cook, M.D.12, Nadine Abdallah I, MD13, Moritz Binder, MD, MPH14, Eli Muchtar, MD15, Rahma Warsame, MD16, Taxiarchis Kourelis, MD17, Ronald Go, MD18, Yi Hwa, DNP19, Miriam Hobbs, CNP20, Amie Fonder, PA-C21, Yi Lin Jr, MD, PhD22, Linda Baughn, PhD23, Morie Gertz24, S. Vincent Rajkumar, MD25, Wilson Gonsalves, MD26
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, United States
3 Mayo Clinic, Rochester, United States
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Rochester, United States
7 Mayo Clinic, Rochester, United States
8 Mayo Clinic, Rochester, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, United States
11 Mayo Clinic, Rochester, United States
12 Mayo Clinic, Rochester, United States
13 Mayo Clinic, Rochester, United States
14 Mayo Clinic, Rochester, United States
15 Mayo Clinic, Rochester, United States
16 Mayo Clinic, Rochester, United States
17 Mayo Clinic, Rochester, United States
18 Mayo Clinic, Rochester, United States
19 Mayo Clinic, Rochester, United States
20 Mayo Clinic, Rochester, United States
21 Mayo Clinic, Rochester, United States
22 Mayo Clinic, Rochester, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, United States
25 Mayo Clinic, Rochester, United States
26 Mayo Clinic, Rochester, United States

INTRODUCTION

Primary plasma cell leukemia (pPCL), defined by the presence of ≥5% circulating plasma cells on peripheral smear, is enriched for the primary cytogenetic abnormality t(11;14), which is present in approximately half of patients. Although pPCL overall carries a poorer prognosis than multiple myeloma (MM), patients with t(11;14) pPCL have fewer secondary high-risk cytogenetic abnormalities (HRCAs) and superior survival compared with pPCL patients lacking t(11;14). Whether patients with t(11;14) pPCL differ from those with t(11;14) MM in their clinical presentation and outcomes—and whether secondary HRCAs at the time of diagnosis have a differential prognostic impact despite the shared primary t(11;14) cytogenetic lesion—remains less clear.

METHODS

Consecutive patients with newly diagnosed pPCL and MM, seen at our institution's cancer center between September 2012 and December 2023, were included for retrospective analysis. Patient demographics, disease characteristics, treatment regimens, and clinical outcomes were collected from the electronic health record. Secondary HRCAs were defined by the presence of deletion 17p or monosomy 17, gain or amplification 1q, or deletion 1p. Time to next treatment (TTNT) after first line therapy and overall survival (OS) analysis were performed using the Kaplan-Meier method. Statistical analyses were performed using the SAS biostatistical software JMP 17.0.1 (SAS Institute Inc).

RESULTS

We included 42 patients with pPCL and 158 with MM harboring t(11;14). Median age was 66 years across the cohort. Age ≥75 years was similar between groups (17% vs. 20%, P = 0.67). Compared with MM, patients with pPCL more frequently presented with hemoglobin <10 g/dL (57% vs. 29%, P = 0.0017), calcium >11 mg/dL (48% vs. 5%, P < 0.0001), creatinine >2 mg/dL (35% vs. 12%, P = 0.0005), a higher prevalence of secondary HRCAs (50% vs. 26%, P = 0.0027), and greater bone marrow plasma cell involvement (79% vs. 51%, P < 0.0001).

Though first-line treatments for these diseases changed over the course of follow-up in this study, those used in patients with pPCL were akin to those in MM. Rates of induction with doublet therapy containing a proteasome inhibitor (29 vs. 32%, P = 0.70), triplet therapy not containing an anti-CD38 monoclonal antibody (CD38 mAb) (40 vs. 40%, P = 0.94) and any use of CD38 mAb-based induction (27% vs. 19%, P = 0.269) were similar. The proportion of patients undergoing upfront ASCT (44% vs. 34%, P = 0.317) was also comparable. After a median follow-up of 95 months (mos) (95% CI, 88–102), median TTNT was significantly shorter in pPCL than MM (19 vs. 37 mos, P = 0.001), whereas the frequency of symptomatic first progression defined by the development of CRAB features or extramedullary disease was similar (26% vs. 27%, P = 0.92).

After stratification by secondary HRCAs, pPCL patients without additional HRCAs (N = 21) had a trend towards shorter median TTNT than those with MM without additional HRCAs (N = 117) (21 vs. 39 mos, P = 0.059). Among patients with secondary HRCAs, median TTNT was significantly shorter in pPCL (N = 21) compared with MM (N = 41) (19 vs. 30 mos, P = 0.014).

At the time of analysis, 96 patients (48%) had died. Patients with pPCL had significantly shorter median OS compared to MM (79 mos vs 111 mos, p = 0.047). When analyzed by HRCA, pPCL patients without additional HRCAs (N = 21) had median OS of 101 mos compared to 116 mos for MM without additional HRCAs (N = 117) (p = 0.348). Those pPCL patients with additional HRCAs (N = 21) had a median OS of 41 mos compared to 75 mos for MM patients with additional HRCAs (N = 41) (p = 0.386).

CONCLUSIONS

Among patients harboring the primary t(11;14) cytogenetic abnormality, pPCL presented with a more aggressive clinical phenotype and nearly twice the prevalence of secondary HRCAs compared with MM. Overall, patients with t(11;14) pPCL experienced shorter TTNT and inferior OS compared to t(11;14) MM. However, stratification by secondary HRCAs appears to attenuate the differences in OS, especially among those patients without HRCAs, suggesting that the excess burden of secondary HRCAs contributes substantially to the adverse prognosis of pPCL. Nevertheless, TTNT remained consistently shorter in pPCL compared to MM, even after stratification by secondary HRCAs, suggesting that additional biological factors beyond secondary HRCAs contribute to the aggressive clinical behavior of t(11;14) pPCL.

Daniel Packard, MD, MSc: No relevant conflicts of interest to declare.